Literature DB >> 29779168

Thyroid cancer-related bone metastases: increasingly good prospects for treatment.

Leonidas H Duntas1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29779168     DOI： 10.1007/s12020-018-1616-2

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  12 in total

1.  Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.

Authors:  M Schlumberger; C Challeton; F De Vathaire; J P Travagli; P Gardet; J D Lumbroso; C Francese; F Fontaine; M Ricard; C Parmentier
Journal:  J Nucl Med       Date:  1996-04       Impact factor: 10.057

2.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

3.  Selective embolization with N-butyl cyanoacrylate for metastatic bone disease.

Authors:  Giuseppe Rossi; Andreas F Mavrogenis; Eugenio Rimondi; Lucia Braccaioli; Teresa Calabrò; Pietro Ruggieri
Journal:  J Vasc Interv Radiol       Date:  2011-03-02       Impact factor: 3.464

4.  Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer.

Authors:  Zhong-Ling Qiu; Hong-Jun Song; Yan-Hong Xu; Quan-Yong Luo
Journal:  J Clin Endocrinol Metab       Date:  2011-07-27       Impact factor: 5.958

Review 5.  Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2017-05-02       Impact factor: 3.959

Review 6.  Modern Palliative Treatments for Metastatic Bone Disease: Awareness of Advantages, Disadvantages, and Guidance.

Authors:  Andreas F Mavrogenis; Andrea Angelini; Christos Vottis; Elisa Pala; Teresa Calabrò; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Clin J Pain       Date:  2016-04       Impact factor: 3.442

Review 7.  Inhibitors of sclerostin: emerging concepts.

Authors:  Matthew T Drake; Joshua N Farr
Journal:  Curr Opin Rheumatol       Date:  2014-07       Impact factor: 5.006

8.  Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.

Authors:  G Mazziotti; A M Formenti; M B Panarotto; E Arvat; A Chiti; A Cuocolo; M E Dottorini; C Durante; L Agate; S Filetti; F Felicetti; A Filice; L Pace; T Pellegrino; M Rodari; M Salvatori; C Tranfaglia; A Versari; D Viola; S Frara; A Berruti; A Giustina; R Giubbini
Journal:  Endocrine       Date:  2017-11-06       Impact factor: 3.633

Review 9.  Bone-Targeted Therapies in Cancer-Induced Bone Disease.

Authors:  Sofia Sousa; Philippe Clézardin
Journal:  Calcif Tissue Int       Date:  2017-10-27       Impact factor: 4.333

10.  Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.

Authors:  Brian Hung-Hin Lang; Kai Pun Wong; Chung Yeung Cheung; Koon Yat Wan; Chung-Yau Lo
Journal:  Ann Surg Oncol       Date:  2012-10-28       Impact factor: 5.344
View more
  2 in total

1.  An analysis of clinical values of MRI, CT and X-ray in differentiating benign and malignant bone metastases.

Authors:  Chun Xiong; Xian Xu; Huiling Zhang; Bo Zeng
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  Papillary thyroid microcarcinoma with contralateral large humerus metastasis and cervical lymph node metastasis: A case report.

Authors:  Yi Gong; Shixiong Tang; Wanlin Tan; Liyan Liao; Xiaodu Li; Chengcheng Niu
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.